Patients with triple-negative breast cancer (TNBC), whose tumours lack ER, PR and HER2 expression, do not benefit from the current development of targeted therapies, with treatment options mostly relying on primary surgery, radiotherapy and chemotherapy cocktail [9]. The gene discussed is ERBB2; the disease is neoplasm.